In vivo evaluation of [123I]-4-(2-(bis(4-fluorophenyl)methoxy)ethyl)-1-(4-iodobenzyl)piperidine, an iodinated SPECT tracer for imaging the P-gp transporter

Nuclear Medicine and Biology

Volumn 37, Issue 4, 2010, Pages 469-477

  De Bruyne, Sylvie ^a   Wyffels, Leonie ^a   Boos, Terrence L ^b   Staelens, Steven ^a   Deleye, Steven ^a   Rice, Kenner C ^b   De Vos, Filip ^a  

^a GHENT UNIVERSITY   (Belgium)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

123I 4 (2 (bis(4 fluorophenyl)methoxy)ethyl) 1 (4 iodobenzyl)piperidine; Brain; P gp; SPECT

Indexed keywords

4 [2 [BIS (4 FLUOROPHENYL)METHOXY]ETHYL] 1 (4 IODOBENZYL)PIPERIDINE I 123; CYCLOSPORIN A; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; TRACER; UNCLASSIFIED DRUG; (123I) 4 (2 (BIS(4 FLUOROPHENYL)METHOXY)ETHYL) 1 (4 IODOBENZYL)PIPERIDINE; (123I)-4-(2-(BIS(4-FLUOROPHENYL)METHOXY)ETHYL)-1-(4-IODOBENZYL)PIPERIDINE; CYCLOSPORIN; DIAGNOSTIC AGENT; PIPERIDINE DERIVATIVE; PLASMA PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG STABILITY; DRUG STRUCTURE; DRUG UPTAKE; GENE DELETION; IMAGE ANALYSIS; IN VIVO STUDY; MALE; MOLECULAR IMAGING; MOUSE; NEUROIMAGING; NONHUMAN; PLASMA PROTEIN BINDING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRUCTURE ACTIVITY RELATION; TISSUE DISTRIBUTION; WILD TYPE; ANIMAL; BRAIN; CHEMISTRY; DRUG EFFECT; GENE INACTIVATION; GENETICS; HALOGENATION; METABOLISM; METHODOLOGY; SCINTISCANNING; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; BLOOD PROTEINS; BRAIN; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE KNOCKOUT TECHNIQUES; HALOGENATION; MALE; MICE; P-GLYCOPROTEIN; PIPERIDINES; RADIOACTIVE TRACERS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 77952546790     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2009.10.006     Document Type: Article

References (53)

1. Ambudkar S.V., Kimchi-Sarfaty C., Sauna Z.E., Gottesman M. P-glycoprotein: from genomics to mechanism. Oncogene 2003, 22:7468-7485.
2. Bosch I., Croop J.M. P-glycoprotein structure and evolutionary homologies. Cytotechnology 1998, 27:1-30.
3. Gottesman M.M., Pastan I., Ambudkar S. P-glycoprotein and multidrug resistance. Curr Opin Genet Dev 1996, 6:610-617.
4. Hsu S.I.H., Lothstein L., Horwitz S.B. Differential overexpression of three mdr gene family members in multidrugresistance J774.2 mouse cells. Evidence that distinct P-glycoprotein precursors are encoded by unique mdr genes. J Biol Chem 1989, 264:12053-12062.
5. Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., Willingham M.C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 1987, 84:7735-7738.
6. Tanigawara Y. Role of P-glycoprotein in drug disposition. Ther Drug Monit 2000, 22:137-140.
7. Schinkel A.H., Jonker J.W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2003, 55:3-29.
8. Cordon-Cardo C., O'Brien J.P., Casals D., Rittman-Grauer L., Biedler J.L., Melamed M.R., et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989, 86:695-698.
9. Löscher W., Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther 2002, 301:7-14.
10. Luna-Tortós C., Fedrowitz M., Löscher W. Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology 2008, 55:1364-1375.
11. Löscher W. Drug transporters in the epileptic brain. Epilepsia 2007, 48:8-13.
12. Kim R.B., Fromm M.F., Wandel C., Leake B., Wood A.J.J., Roden D.M., et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998, 101:289-294.
13. Szabo D., Szabo G., Ocsovszki I., Aszalos A., Molnar J. Anti-psychotic drugs reverse multidrug resistance of tumor cell lines and human AML cells ex-vivo. Cancer Lett 1999, 139:115-119.
14. Schinkel A.H., Wagenaar E., Mol C.A.A.M., Van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996, 97:2517-2524.
15. Schinkel A.H. P-glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 1999, 36:179-194.
16. Linnet K., Ejsing T.B.A. review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs. Eur Neuropsychopharmacol 2008, 18:157-169.
17. Löscher W., Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 2005, 6:591-602.
18. Zhou S.F. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 2008, 38:802-832.
19. Kwan P., Brodie M.J. Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia 2005, 46:224-235.
20. Turgut G., Bastemir M., Turgut S., Akin F., Kursunluoglu R., Kaptanoglu B. P-gycoprotein polymorphism in hypo- and hyper-thyroidism patients. Mol Biol Rep 2008, 35:693-698.
21. Kortekaas R., Leenders K.L., Van Oostrom J.C.H., Vaalburg W., Bart J., Willemsen A.T.M., et al. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 2005, 57:176-179.
22. Langford D., Grigorian A., Hurford R., Adame A., Ellis R.J., Hansen L., et al. Altered P-glycoprotein expression in AIDS patients with HIV encephalitis. J Neuropathol Exp Neurol 2004, 63:1038-1046.
23. Lam F.C., Liu R., Lu P., Shapiro A.B., Renoir J.M., Sharom F.J., et al. B-amyloid efflux mediated by p-glycoprotein. J Neurochem 2001, 76:1121-1128.
24. Vogelgesang S., Cascorbi I., Schroeder E., Pahnke J., Kroemer H.K., Siegmund W., et al. Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 2002, 12:535-541.
25. Gottesman M.M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993, 62:385-427.
26. Gottemann M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2002, 2:48-58.
27. Elsinga P.H., Franssen E.J.F., Hendrikse N.H., Fluks L., Weemaes A.M.A., Van Der Graaf W.T.A., et al. Carbon-11-labeled daunorubicin and verapamil for probing P-glycoprotein in tumors with PET. J Nucl Med 1996, 37:1571-1575.
28. Hendrikse N.H., Schinkel A.H., de Vries E.G.E., Fluks E., Van Der Graaf W.T.A., Willemsen A.T.M., et al. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br J Pharmacol 1998, 124:1413-1418.
29. 11C]verapamil. J Pharmacol Exp Ther 2006, 316:647-653.
30. 11C-colchicine for PET imaging of multiple drug resistance. J Nucl Med 2000, 41:493-501.
31. 18F-paclitaxel in nonhuman primates. J Nucl Med 2003, 44:1330-1339.
32. 11C]carvedilol reveals P-glycoprotein modulation kinetics. Br J Pharmacol 2005, 145:1045-1051.
33. Lewis J.S., Dearling J.L., Sosabowski J.K., Zweit J., Carnochan P., Kelland L.R., et al. Copper bis(diphosphine) complexes: radiopharmaceuticals for the detection of multi-drug resistance in tumours by PET. Eur J Nucl Med 2000, 27:638-646.
34. 64Cu-labeled monocationic copper(II) complex. Nucl Med Biol 2002, 29:289-294.
35. 11C]N-Desmethyl-loperamide as a new and improved PET radiotracer for imaging P-gp function. JMed Chem 2008, 51:6034-6043.
36. 11C-Loperamide and its N-desmethyl radiometabolite are avid substrates for brain permeability-glycoprotein efflux. J Nucl Med 2008, 49:649-656.
37. Sasongko L., Link J.M., Muzi M., Mankoff D.A., Yang X.D., Collier A.C., et al. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ther 2005, 77:503-514.
38. 11C]verapamil in epilepsy patients. Eur J Nucl Med Mol Imaging 2007, 35:116-123.
39. Bartels A.L., van Berckel B.N.M., Lubberink M., Luurtsema G., Lammertsma A.A., Leenders K.L. Blood-brain barrier P-glycoprotein function is not impaired in early Parkinson's disease. Parkinsonism Relat Disord 2008, 14:505-508.
40. Kostakoglu L., Elahi N., Kïratlï P., Ruacan S., Sayek I., Baltalï E., et al. Clinical validation of the influence of P-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors. J Nucl Med 1997, 38:1003-1008.
41. 99mTc-sestamibi as an agent for imaging P-glycoprotein-mediated multi-drug resistance: in vitro and in vivo studies in a rat breast tumour cell line and its doxorubicin-resistant variant. Nucl Med Commun 1995, 16:253-257.
42. Ballinger J.R., Bannerman J., Boxen I., Firby P., Hartman N.G., Moore M.J. Technetium-99m-Tetrofosmin as a substrate for P-glycoprotein: in vitro studies in multidrug-resistant breast tumor cells. J Nucl Med 1996, 37:1578-1582.
43. Hendrikse N.H., Franssen E.J.F., van der Graaf W.T.A., Meijer C., Piers D.A., Vaalburg W., et al. Tc-99m-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein. Br J Cancer 1997, 77:353-358.
44. Barbarics E., Kronauge J.F., Cohen D., Davison A., Jones A.G., Croop J.M. Characterization of P-glycoprotein transport and inhibition in vivo. Cancer Res 1998, 58:276-282.
45. 123I]-4-(2-(bis(4-fluorophenyl)methoxy)ethyl)-1-(4-iodobenzyl)piperidine as a selective tracer for imaging the dopamine transporter. J Label Compd Radiopharm 2009, 52:304-311.
46. Gandelman M.S., Baldwin R.M., Zoghbi S.S., Zea-Ponce Y., Innis R.B. Evaluation of ultrafiltration for the free fraction determination of single photon emission computerized tomography (SPECT) radiotracers: β-CIT, IBF and iomazenil. J Pharm Sci 1994, 83:1014-1019.
47. Fowler J.S., Kroll C., Ferrieri R., Alexoff D., Logan J., Dewey S.L., et al. PET studies of d- methamphetamine pharmacokinetics in primates: comparison with l-methamphetamine and (-)-cocaine. J Nucl Med 2007, 48:1724-1732.
48. De Vries E.F.J., Doorduin J., Vellinga N.A.R., Van Waarde A., Dierckx R.A., Klein H.C. Can celecoxib affect P-glycoprotein-mediated drug efflux? A microPET study. Nucl Med Biol 2008, 35:459-466.
49. Elsinga P.H., Hendrikse N.H., Bart J., Van Waarde A., Vaalburg W. Positron emission tomography studies on binding of central nervous system drugs and P-glycoprotein function in the rodent brain. Mol Imaging Biol 2005, 7:37-44.
50. Syvanen S., Blomquist G., Sprycha M., Hoglund A.U., Roman M., Eriksson O., et al. Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood-brain barrier can be studied with PET. Neuroimage 2006, 32:1134-1141.
51. 11C]Verapamil as PET-tracers for measuring P-glycoprotein function: in vitro and in vivo evaluation. Nucl Med Biol 2003, 30:747-751.
52. 11C]Verapamil measured with PET. Neuroimage 2003, 20:1775-1782.
53. Piwnica-Worms D., Kesarwala A.H., Pichler A., Prior J.L., Sharma V. Single photon emission computed tomography and positron emission tomography imaging of multi-drug resistant P-glycoprotein-Monitoring a transport activity important in cancer, blood-brain barrier function and Alzheimer's disease. Neuroimaging Clin N Am 2006, 16:575-589.